Recent research has focused on finding ligands with dual- or pan-PPAR agonist effects to provide patients with access to drugs with more beneficial effects (e.g., normalization of insulin resistance, reduction of plasma lipids, etc.)and fewer adverse effects (e.g., slowing of heart failure progression) compared to isoform-selective ligands (PPARα, PPARβ/δ, or PPARγ) [48,49,50,51]. This evidence concerns the gene PPARA and heart failure.